741 related articles for article (PubMed ID: 27452466)
61. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
[TBL] [Abstract][Full Text] [Related]
62. Killing SCLC: insights into how to target a shapeshifting tumor.
Sutherland KD; Ireland AS; Oliver TG
Genes Dev; 2022 Mar; 36(5-6):241-258. PubMed ID: 35318269
[TBL] [Abstract][Full Text] [Related]
63. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.
George J; Walter V; Peifer M; Alexandrov LB; Seidel D; Leenders F; Maas L; Müller C; Dahmen I; Delhomme TM; Ardin M; Leblay N; Byrnes G; Sun R; De Reynies A; McLeer-Florin A; Bosco G; Malchers F; Menon R; Altmüller J; Becker C; Nürnberg P; Achter V; Lang U; Schneider PM; Bogus M; Soloway MG; Wilkerson MD; Cun Y; McKay JD; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Lemaitre N; Soltermann A; Weder W; Tischler V; Brustugun OT; Lund-Iversen M; Helland Å; Solberg S; Ansén S; Wright G; Solomon B; Roz L; Pastorino U; Petersen I; Clement JH; Sänger J; Wolf J; Vingron M; Zander T; Perner S; Travis WD; Haas SA; Olivier M; Foll M; Büttner R; Hayes DN; Brambilla E; Fernandez-Cuesta L; Thomas RK
Nat Commun; 2018 Mar; 9(1):1048. PubMed ID: 29535388
[TBL] [Abstract][Full Text] [Related]
64. Molecular Subtypes of Extra-pulmonary Neuroendocrine Carcinomas Identified by the Expression of Neuroendocrine Lineage-Specific Transcription Factors.
Metovic J; La Salvia A; Rapa I; Napoli F; Birocco N; Pia Bizzi M; Garcia-Carbonero R; Ciuffreda L; Scagliotti G; Papotti M; Volante M
Endocr Pathol; 2022 Sep; 33(3):388-399. PubMed ID: 35608806
[TBL] [Abstract][Full Text] [Related]
65. In-depth proteomic analysis reveals unique subtype-specific signatures in human small-cell lung cancer.
Szeitz B; Megyesfalvi Z; Woldmar N; Valkó Z; Schwendenwein A; Bárány N; Paku S; László V; Kiss H; Bugyik E; Lang C; Szász AM; Pizzatti L; Bogos K; Hoda MA; Hoetzenecker K; Marko-Varga G; Horvatovich P; Döme B; Schelch K; Rezeli M
Clin Transl Med; 2022 Sep; 12(9):e1060. PubMed ID: 36149789
[TBL] [Abstract][Full Text] [Related]
66. ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis.
Fujiwara T; Hiramatsu M; Isagawa T; Ninomiya H; Inamura K; Ishikawa S; Ushijima M; Matsuura M; Jones MH; Shimane M; Nomura H; Ishikawa Y; Aburatani H
Lung Cancer; 2012 Jan; 75(1):119-25. PubMed ID: 21737174
[TBL] [Abstract][Full Text] [Related]
67. Polymorphism in ASCL1 target gene DDC is associated with clinical outcomes of small cell lung cancer patients.
Kim JH; Lee SY; Choi JE; Do SK; Lee JH; Hong MJ; Kang HG; Lee WK; Shin KM; Jeong JY; Choi SH; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
Thorac Cancer; 2020 Jan; 11(1):19-28. PubMed ID: 31691490
[TBL] [Abstract][Full Text] [Related]
68. Taking SCLC on a Bad LSD(1) Trip One NOTCH Further.
Kim J; Sage J
Trends Mol Med; 2019 Apr; 25(4):261-264. PubMed ID: 30852141
[TBL] [Abstract][Full Text] [Related]
69. REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.
Masawa M; Sato-Yazawa H; Kashiwagi K; Ishii J; Miyata-Hiramatsu C; Iwamoto M; Kohno K; Miyazawa T; Onozaki M; Noda S; Shimizu Y; Niho S; Yazawa T
Am J Pathol; 2022 Jun; 192(6):847-861. PubMed ID: 35367201
[TBL] [Abstract][Full Text] [Related]
70. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.
Romero OA; Torres-Diz M; Pros E; Savola S; Gomez A; Moran S; Saez C; Iwakawa R; Villanueva A; Montuenga LM; Kohno T; Yokota J; Sanchez-Cespedes M
Cancer Discov; 2014 Mar; 4(3):292-303. PubMed ID: 24362264
[TBL] [Abstract][Full Text] [Related]
71. Differences of molecular expression mechanisms among neural cell adhesion molecule 1, synaptophysin, and chromogranin A in lung cancer cells.
Kashiwagi K; Ishii J; Sakaeda M; Arimasu Y; Shimoyamada H; Sato H; Miyata C; Kamma H; Aoki I; Yazawa T
Pathol Int; 2012 Apr; 62(4):232-45. PubMed ID: 22449227
[TBL] [Abstract][Full Text] [Related]
72. The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy.
Tendler S; Kanter L; Lewensohn R; Ortiz-Villalón C; Viktorsson K; De Petris L
PLoS One; 2020; 15(10):e0240973. PubMed ID: 33104707
[TBL] [Abstract][Full Text] [Related]
73. MYCL1 Amplification and Expression of L-Myc and c-Myc in Surgically Resected Small-Cell Lung Carcinoma.
Qin J; Xie F; Li C; Han N; Lu H
Pathol Oncol Res; 2021; 27():1609775. PubMed ID: 34257619
[No Abstract] [Full Text] [Related]
74. Involvement of intermediate filament nestin in cell growth of small-cell lung cancer.
Takakuwa O; Maeno K; Kunii E; Ozasa H; Hijikata H; Uemura T; Kasai D; Ohkubo H; Miyazaki M; Oguri T; Niimi A
Lung Cancer; 2013 Aug; 81(2):174-9. PubMed ID: 23706418
[TBL] [Abstract][Full Text] [Related]
75. [Heterogeneity of small cell lung cancer: biological and clinicopathological implications].
Megyesfalvi Z; Bárány N; Valkó Z; Bugyik E; Paku S; Berta J; Lantos A; Fillinger J; Moldvay J; Bogos K; Rezeli M; Gálffy G; Lang C; Lohinai Z; Hécz R; Lovas T; Rényi-Vámos F; László V; Döme B
Magy Onkol; 2020 Sep; 64(3):243-255. PubMed ID: 34608895
[TBL] [Abstract][Full Text] [Related]
76. Hypermethylation of adjacent CpG sites is negatively correlated with the expression of lineage oncogene ASCL1 in pulmonary neuroendocrine tumors.
Truong N; Chun SM; Kim TI; Suh YA; Jang SJ
Tumour Biol; 2017 Jun; 39(6):1010428317706225. PubMed ID: 28621224
[TBL] [Abstract][Full Text] [Related]
77. Clinical and morphological features of large-cell neuroendocrine carcinomas and small-cell lung carcinomas expressing the DLL3 and ASCL1 oncoproteins.
Prieto TG; Baldavira CM; Machado-Rugolo J; Olivieri EHR; Silva ECAD; Silva VG; Ab'Saber AM; Takagaki TY; Capelozzi VL
Braz J Med Biol Res; 2023; 56():e12921. PubMed ID: 38126617
[TBL] [Abstract][Full Text] [Related]
78. Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients.
Semenova EA; Kwon MC; Monkhorst K; Song JY; Bhaskaran R; Krijgsman O; Kuilman T; Peters D; Buikhuisen WA; Smit EF; Pritchard C; Cozijnsen M; van der Vliet J; Zevenhoven J; Lambooij JP; Proost N; van Montfort E; Velds A; Huijbers IJ; Berns A
Cell Rep; 2016 Jul; 16(3):631-43. PubMed ID: 27373156
[TBL] [Abstract][Full Text] [Related]
79. Genetic variation in an miRNA-1827 binding site in MYCL1 alters susceptibility to small-cell lung cancer.
Xiong F; Wu C; Chang J; Yu D; Xu B; Yuan P; Zhai K; Xu J; Tan W; Lin D
Cancer Res; 2011 Aug; 71(15):5175-81. PubMed ID: 21676885
[TBL] [Abstract][Full Text] [Related]
80. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer.
Feng M; Matoso A; Epstein G; Fong M; Park YH; Gabrielson A; Patel S; Czerniak B; Compérat E; Hoffman-Censits J; Kates M; Kim S; McConkey D; Choi W
Eur Urol; 2024 Jun; 85(6):523-526. PubMed ID: 37380560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
